Bluetongue virus vaccine: conventional to modern approach Bluetongue (BT) is an economically important, infectious and non-contagious disease of ruminant animals. BT disease is caused by bluetongue virus (BTV) of the genus Orbivirus (the family Reoviridae). BTV is transmitted by certain species of biting midges of the genus Culicoides Active Ingredient (s): Contains bluetongue vaccine modified live virus, type 10. Penicillin and streptomycin are added as preservatives. The advantages of the tissue culture technique for viral vaccine production are well understood and widely accepted in medical circles § 113.303 Bluetongue Vaccine. Bluetongue Vaccine shall be prepared from virus-bearing cell culture fluids. Only Master Seed which has been established as pure, safe, and immunogenic shall be used for preparing the seeds for vaccine production. All serials of vaccine shall be prepared from the first through the tenth passage from the Master Seed Since there is no curative treatment for BTV-infected animals, prophylactic immunization of susceptible species remains the most effective and practical control measure against bluetongue in endemic regions. In the U.S., the only vaccine approved for national use is a monovalent attenuated modified-live vaccine against serotype 10
Isolation of 8 serotypes of bluetongue virus (BTV) in Australia has led to widespread debate on how to prepare for an outbreak of bluetongue disease and the type of vaccine best suited to control bluetongue in Australia. This article describes the vaccine options under consideration by research work At present the only vaccines used against bluetongue (BT) disease are live-attenuated virus vaccines. Since viruses with RNA genomes such as BT virus (BTV) have a high frequency of mutations, live virus vaccines could have breakthroughs (vaccine failures) and mutate into virulent strains
Bluetongue virus proteins derived from baculovirus expression vectors have been administered in different combinations to sheep, a vertebrate host susceptible to bluetongue virus, and the neutralizing antibody responses were measured. Vaccinated sheep were subsequently challenged, and the indices of clinical reaction were calculated received a bluetongue virus-contaminated vaccine. Transplacental transmission has been demonstrated in dogs, at least for serotype 11. Disinfection Disinfectants reported to be effective against bluetongue virus include sodium hypochlorite and 3% sodium hydroxide. Sodium hypochlorite, iodine (potassiu Bluetongue virus (BTV) is an orbivirus that infects both domestic and wild ruminants and is transmitted by Culicoides spp. biting midges (Price and Hardy 1954, Borden et al. 1971, Matthews 1982). Among the arboviruses transmitted by Culicoides, BTV has the greatest economic impact (Bath 1989), with losses attributed to effects on animal health. Bluetongue vaccines for sheep and cattle are now available across Britain, with supplies approved for use in vet practices. There is a high risk of an outbreak of Bluetongue (BTV-8) towards the end.. Bluetongue virus (BTV) causes the hemorrhagic disease bluetongue (BT) in ruminants. The best way to control outbreaks is vaccination. Currently, conventionally modified-live and inactivated vaccines are commercially available, which have been successfully used to control BT, but nonetheless have their specific shortcomings
Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective D. Scott McVey1 and N. James MacLachlan2 Abstract Bluetongue (BT) and epizootic hemorrhagic disease (EHD) are noncontagious, insect-transmitted diseases of domestic and wild ruminants caused by related but distin ct viruses After the incursion of bluetongue virus (BTV) into European Mediterranean countries in 1998, vaccination was used in an effort to minimize direct economic losses to animal production, reduce virus circulation and allow safe movements of animals from endemic areas What is bluetongue and what causes it? Bluetongue is a non-contagious, viral disease spread by biting insects. It affects species of ruminants, particularly sheep. Bluetongue causes Vaccines are available for animals deemed to be at high risk of contracting bluetongue, however, these vaccines are not without risk
Bluetongue Vaccine shall be prepared from virus-bearing cell culture fluids. Only Master Seed which has been established as pure, safe, and immunogenic shall be used for preparing the seeds for vaccine production. All serials of vaccine shall be prepared from the first through the tenth passage from the Master Seed Bluetongue (BT) is a haemorrhagic disease of wild and domestic ruminants with a huge economic worldwide impact on livestock. The disease is caused by BT-virus transmitted by Culicoides biting midges and disease control without vaccination is hardly possible. Vaccination is the most feasible and cost-effective way to minimize economic losses Bluetongue virus is a substantial health risk to sheep and other ruminants. Livestock can be protected by vaccination, but as described in this Review, current vaccines can have severe drawbacks. Prospects of Next-Generation Vaccines for Bluetongue. Bluetongue (BT) is a haemorrhagic disease of wild and domestic ruminants with a huge economic worldwide impact on livestock. The disease is caused by BT-virus transmitted by Culicoides biting midges and disease control without vaccination is hardly possible
Intervet's Bluetongue vaccine recently gained a temporary license in France. Based on this license, other member states of the European Union can allow usage of the vaccine to control the disease. As the global leader in the development and supply of vaccines to support animal health and welfare, Intervet has been actively working on a. REVIEWS Prospects for improved bluetongue vaccines Polly Roy, Mark Boyce and Robert Noad Abstract | Bluetongue has been recognized as a viral disease of livestock for more than 100 years. Repeated incursions of Bluetongue into Europe since 1998 have been particularly devastating for highly sensitive European fine-wool sheep breeds, and have. - For bluetongue vaccines (authorised under exception al circumstances or standard authorisations) the following fee reductions will apply: 100% of the annual fee for a ny bluetongue vaccine that has not been marketed within the EU/EEA during the year and 0% for any bluetongue vaccine that has been marketed wi thin the EU/EEA during the year The control of bluetongue is different in areas where the disease is not endemic. During an outbreak, when one or a limited number of serotypes may be involved, vaccination strategy depends on the serotype(s) causing infection. Use of vaccine strains other than the one(s) causing infection affords little or no protection and is not recommended
India's first vaccine for bluetongue disease that is increasingly afflicting sheep and goat population across the country was launched by the veterinary biological company Indian Immunologicals. Vaccination is the best way to fight the specific strain of bluetongue virus rampaging through cattle and sheep in northern EU countries and vast amounts of vaccine may well be needed, the EU. to protect animals from bluetongue. Consult your vet about the benefits of doing so and the availability of vaccine if this is something you are considering. Meat and milk from vaccinated animals is safe for consumption. • Maintain good biosecurity such as washing equipment after use. For the latest information and useful links log ont BTVPUR is a vaccine used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges. The vaccine is used to prevent viraemia (the presence of viruses in the blood) and reduce the signs of the disease. The vaccine contains inactivated (killed) bluetongue virus Bluetongue (BTV) Bluetongue is an insect-borne, viral disease affecting sheep, cattle, deer, goats and camelids (camels, llamas, alpacas, guanaco and vicuña). Although sheep are most severely affected, cattle are the main mammal reservoir of the virus and are critical in the disease epidemiology. The disease is non-contagious and is only.
N. James Maclachlan: Bluetongue vaccines in the Unated States of America; Outcome of other discussions at EU level on bluetongue vaccination. Meeting with vaccine producers on availability of vaccines against bluetongue, Brussels 21 November 2007; Working Group on an EU harmonised strategy on vaccination against Bluetongue, Brussels 5 November 200 The vaccine was launched with an aim to minimise the economic loss of the animal farming community that occurs due to bluetongue disease. This is India's first vaccine for bluetongue disease The usefulness of bluetongue vaccine is tested extensively in Tamil Nadu, Andhra Pradesh, Karnataka and Maharashtra. There is wide appreciation from the farming community regarding effectiveness of this vaccine.. Bluetongue, which is transmitted by culicoides, was first reported in India during 1964
Since 1998, Bluetongue virus (BTV)-serotypes 1, 2, 4, 9, and 16 have invaded European countries around the Mediterranean Basin. In 2006, a huge BT outbreak started after incursion of BTV serotype 8 (BTV8) in North-Western Europe. IN 2008, BTV6 and BTV11 were reported in the Netherlands and Germany, and in Belgium, respectively. In addition, Toggenburg orbivirus (TOV) was detected in 2008 in. . Bluetongue is a viral disease of both sheep and cattle, with sheep being the most severely affected. The virus is spread by biting midges, so the risk.
The first year of vaccination involved 750,000 sheep, 121,000 cattle, 30,000 goats and 7000 water buffaloes; in the second, the number of vaccinated animals rose to 1,026,000 sheep, 283,000 cattle, 41,000 goats and 43,000 water buffaloes.Bluetongue-vaccine virus (BTVV) transmission in the field has never been described; nevertheless, Murray and.
Bluetongue is a viral disease affecting sheep, cattle, deer, goats and camelids (camels, llamas, alpacas, guanaco and vicuña). Although sheep are most severely affected, cattle are the main mammalian reservoir of the virus and are very important in the epidemiology of the disease. The vaccines also do not act immediately with cattle. Bluevac BTV is a vaccine used in cattle and sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus, which is transmitted by midges. Signs of the disease include fever and skin ulceration, as well as swelling and occasionally blueish discolouration of the tongue mainly seen in sheep Bluevac BTV8® Bluetongue vaccine/ sheep + cattle 200 µg/dose sheep 400 µg/dose cattle 26, 50, 126 doses in sheep 13, 25, 63 doses in cattle Circovac® Porcine circovirus vaccine/ pigs (gilts, sows and piglets) 200 µg/dose sows 50 µg/dose piglets 5, 25 doses in gilts, sow Scientists have developed a faster method of producing an effective vaccine for the devastating animal disease caused by Bluetongue virus (BTV); a virus that has infected and killed thousands of. A vaccine to prevent the spread of bluetongue virus, which is expected to reach the south of England later this summer, will soon be made available to UK farmers
(1996) Expression of the major core structural protein (VP7) of bluetongue virus, Vaccine 28: 4348-4355. by a recombinant capripox virus, provides partial protection of sheep against a 31. Roy P (2004) Genetically engineered structure-based vaccine for bluetongue virulent heterotypic bluetongue virus challenge . a disease that affects some farm animals, especially sheep and cows, in which the mouth and. Learn more A new study has revealed the atomic structure of the Bluetongue virus, including the means by which it infects healthy host cells. Scientists hope to use this information to aid in the creation of vaccines and drug treatments for bluetongue disease
Better vaccines will be important to help combat the threat that Bluetongue poses to livestock farming in the UK and abroad. Bluetongue is a viral disease of cows and sheep that is transmitted by. . Savini G, Monaco F, Calistri P, Panichi G, Ruiu A, Leone A, Caporale V: Neutralising antibody response in cattle after vaccination with monovalent modified-live vaccine against bluetongue virus serotype 2. Vet Ital 2004, 40(4):668-670. 24. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S: Vaccines against bluetongue in Europe Bluetongue is a vector-borne viral disease of domestic and wild ruminants such as sheep, goats, cattle and deer. It is transmitted through the bites of certain species of Culicoides midges. Currently there are 26 known serotypes of the virus, with different rates of virulence and mortality. Bluetongue does not affect humans, but it can cause considerable damage to livestock populations Introduction. Bluetongue (BT) is an infectious, non contagious arthropod-borne disease of ruminants caused by Bluetongue virus (BTV), prototype species of the genus Orbivirus, within the family Reoviridae.Twenty four serotypes of bluetongue virus have been identified till date (Davies et al., 1992).. India has significant population of domestic and wild ruminants which are known to be.
A more effective vaccine. Wageningen Bioveterinary Research developed an innovative prototype vaccine against Bluetongue, which is expected to be more effective than vaccines that are currently available.. Furthermore, the new vaccine can be easily adapted to new virus strains Conference on Vaccination strategy against bluetongue Vaccine combinations used in Italy Serotypes No. of vaccinated sheep and goats No. of vaccinated cattle Serotypes No. of vaccinated sheep and goats No. of vaccinated cattle BTV2 4 074 574 396 165 BTV2-BTV9 1 976 397 896 81 the only vaccines available when that Directive was adopted. The use of those vaccines may lead to an undesired local circulation of the vaccine virus also in unvaccinated animals. (4) In recent years, as a result of new technology, 'inactivated vaccines' against bluetongue have becom
Intervet International has developed a vaccine against Bluetongue serotype 8 for sheep and cattle. It is expected to be available in May. The United Kingdom Department for Environment, Food and Rural Affairs has already placed an order with Intervet to supply 22.5 million doses of the vaccine. Just recently, the European Commission said it is making funds available to co-finance an emergency. Second Generation Candidate Vaccine for Bluetongue Disease. The Australian Experience: Results of a Bluetongue Vaccination Program. Development, Production, and Quality Control of an Industrial Inactivated Vaccine Against African Horse Sickness Virus Serotype 4. Antibody Titers in Horses After Vaccination with African Horse Sickness Virus.
TRICHY: A new vaccine developed by the Tamil Nadu Veterinary and Animal Sciences University (TANUVAS) to prevent bluetongue disease in sheep has hit the market, said its vice-chancellor Dr S. Priced at Rs. 5 for the farmers, the vaccine has been developed to protect the animals against five strains of the 'bluetongue' virus prevalent in the country
Northern European countries want the European Union to let them use a new, killed bluetongue vaccine to get rid of it. In 2002 Italy and Spain started using a vaccine made of live, weakened virus Bluetongue general licence for using inactivated vaccine in a bluetongue-free area . The Secretary of State declared the ending of all bluetongue restricted zones in England on the 5 July 2011. Directive 2012/5/EU amends Council Directive 2000/75/EC to allow inactivated bluetongue vaccine to be used outside of a restricted zone, an
Vesicular stomatitis viral replicons expressing VP2 or similar vaccines based on canarypoxviruses have also been shown to be potentially effective vaccines for bluetongue (48, 49). Vaccines based on reverse genetics include the generation of live attenuated vaccines in which the VP2 and VP5 proteins of BTV-1 and BTV-8 were introduced into an. Bluetongue vaccine : cells and/or antibodies Author(s) Jeggo, M. H. Wardley, R. C. Journal name Vaccine Volume number 3 Issue number 1 Start page 57 End page 58 Total pages 2 Publisher Elsevier Place of publication. The Cabinet has approved the administration of a free vaccine against the bluetongue disease to around half a million sheep, goats and cattle, Agriculture Minister Nicos Kouyialis said on Friday
Bluetongue (BT) is a serious hemorrhagic disease of ruminants caused by bluetongue virus (BTV). Inactive BTV vaccines have been successful in field trials in some areas, and inactivated vaccines are considered safer. However, information about the effect of the viral antigen level on the serological response and efficiency of the inactive BTV-16 vaccine is lacking Bluetongue is an arthropod-borne viral disease of ruminants. Bluetongue virus (BTV) is spread by insect vectors, Culicoides midges, feeding on viraemic animals. All ruminant species are susceptible; however bluetongue is primarily a disease of sheep. Infection in cattle, although of great epidemiological significance, is usually subclinical Fears raised over bluetongue vaccine availability. Drug companies are nervous about producing bluetongue vaccine that may not get used in the UK in the event of an outbreak of the disease, the. 2009 Answer to written question: EU bluetongue vaccine bank (E-6661/08). Brussels. Google Scholar. Venter G. J.& Paweska J. T.. 2007 Virus recovery rates for wild-type and live-attenuated vaccine strains of African horse sickness virus serotype 7 in orally infected South African Culicoides species The NFU has welcomed news that Bluetongue vaccine will be available from mid-July and is now telling farmers to speak to their vets as a matter of urgency. MSD Health has now signed an agreement with CZ Veterinaria S.A. to distribute its BLUEVAC BTV8 vaccine throughout Great Britain and the vaccines produced by Zoetis, Zulvac® 8 Bovis and. Bluetongue is an insect-borne viral disease to which all species of ruminants are susceptible, although sheep are most severely affected. Cattle and goats which appear healthy can carry high levels of the virus and provide a source of further infection. The disease is caused by a virus which is transmitted by certain species of biting midges